Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.47) by 6.38 percent. This is a 25.37 percent increase over losses of $(0.67) per share from the same period last year.